TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for TIEFENBACHER GROUP to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.
The lab is equipped with the latest techniques with full safety protection measurements and will be extended by an additional manufacturing block with special technologies in 2023. The new complex will cover a total of about 4.000 square meters.
TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in the new facilities in Hyderabad. While the operational start of the lab (including small-scale production) is planned for this year, the commercial production for larger quantities in the new manufacturing block is expected for 2024.
For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
